The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 1, 2007, Pages 23-27

  Skultetyova, Dana ^a   Filipova, Slavomira ^b   Riecansky, Igor ^b   Skultety, Jan ^c  

^a NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

^b SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^c State Hospital   (Slovakia)

Author keywords

Adhesive molecules; AT1 receptor; Cytokines; Endothelial dysfunction; Matrix metalloproteinases; Monocyte chemoattractant protein 1; Oxidative stress; Vascular endothelial growth factor

Indexed keywords

4 THIENYLBENZYLAMIDE; AMIDE; ANGIOGENIC FACTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CELL ADHESION MOLECULE; CORTISOL ANTAGONIST; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; FOSINOPRIL; HORMONE ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAGNESIUM OXIDE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; QUINAPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE PHASE RESPONSE; ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME SYNTHESIS; GENE ACTIVATION; HORMONE RECEPTOR INTERACTION; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PATENT; PERIPHERAL VASCULAR DISEASE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RENOVASCULAR DISEASE; REVIEW; STEM CELL;

ANIMALS; ENDOTHELIAL CELLS; FIBRINOLYSIS; HUMANS; INFLAMMATION; OXIDATIVE STRESS; RECEPTOR, ANGIOTENSIN, TYPE 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249285936     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007779606130     Document Type: Review

References (62)

1. Pepine CJ. Clinical implications of endothelial dysfunction. Clin Cardiol 1998; 21: 795-99.
2. Bachetti T. Endothelial dysfunction in chronic heart failure: some new basic mechanisms. Ital Heart J 2000; 1: 656-61.
3. Ganz P, Vita JA. Testing endothelial vasomotor function. Nitric oxide, a multipotent molecule. Circulation 2003; 108: 2049-53.
4. Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis ? Circulation 2004; 109 suppl II: II-27-II- 33.
5. Worcel, M., Sabolinski, M., Tam, S. W., Mcnamara, D. M.: WO06110601A2 (2006).
6. Garvey, D. S.: WO06078995A1 (2006).
7. Garvey, D. S.: WO06102071A1 (2006).
8. Boschmann M, Jordan J, Adams F, et al. Tissue-specific response to interstitial angiotensin II in humans. Hypertension 2003; 41: 37-41.
9. Steele, R. E.: NZ0521855A (2004).
10. Steele, R. E.: US20050059697A1 (2005).
11. Garvey, D. S., Cai, X., Lin, C.-E., Ranatunge, R.R., Stevenson, C. A., Wey, S.-J.: WO06099058A2 (2006).
12. Garvey, D. S.: WO06093864A1 (2006).
13. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacological reviews 2000; 52: 11-34.
14. 1, receptor regulation. Circulation 2002; 105: 530-36.
15. Herman, I. M., Siecwicz, G. J.: US20036521420 (2003).
16. Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium. Diverse signals and effects. Hypertension 2005; 45: 163-69.
17. 2 subtype receptor of angiotensin II. Hypertension 2001; 38: 1150-57.
18. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor. Hypertension 2005; 45: 840-44.
19. Munzel T, Keaney JF,Jr. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001; 104: 1571-74.
20. Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 346: 1999-2001.
21. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-16.
22. Li DY, Zhang YC, Philips MI, et al. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999; 84: 1043-1049.
23. Szmitko PE, Wang CH-H, Weisel RD, et al. Biomarkers of vascular disease linking inflammation to endothelial activation. Part II. Circulation 2003; 108: 2041-2048.
24. 1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: Oxidative stress and atherogenesis. Circulation 2002; 105: 393-96.
25. Loscalzo J. Folate and nitrate-induced endothelial dysfunction. A simple treatment for a complex pathobiology. Circulation 2001; 104: 1086-1088.
26. Pollock DM. Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension 2005; 45: 477-80.
27. Larner, J., Price, J., Brownlee, M., Fonteles, M.: US20060258754A1 ( 2006).
28. Blankenberg S, Rupprecht HJ, Bickel Ch, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-42.
29. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscl Thromb Vasc Biol 2002; 22: 1208-12.
30. Brasier AR, Recinos III A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscl Thromb Vasc Biol 2002; 22: 1257-66.
31. Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997; 79(5A): 3-8.
32. Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol 1997; 79(5A): 24-28.
33. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003; 91(suppl): 30H-7H.
34. Flesch M, Höper A, Dell'Italia L, et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2003; 108: 598-604.
35. Kishore R, Spyridopoulos I, Luedemann C, Losordo DW. Functionally novel tumor necrosis factor-α-modulated CHR-binding protein mediates cyclin A transcriptional repression in vascular endothelial cells. Circ Res 2002; 91: 307-314.
36. Krasinski K, Spyridopoulos I, Kearney M, et al. In vivo blockade of tumor necrosis factor-α accelerates functional endothelial recovery after balloon angioplasty. Circulation 2001; 104: 1754-56.
37. Francis GS. TNF-α and heart failure. The difference between proof of principle and hypothesis testing. Circulation 1999; 99: 3213-14.
38. Sakalova A, Skultetyova D, Bucova M, et al. Zapalove a protizapalov cytokiny pri zhubnych hematologickych ochoreniach. Klinicka onkologie 2003; 16: 19-23.
39. Imaizumi T, Itaya H, Fujita K, et al. Expression of tumor necrosis factor-α in cultured human endothelial cells stimulated with lipopolysaccharide or interleukin-1α. Arterioscler Thromb Vasc Biol 2000; 20: 410-15.
40. Blumm A, Miller H. Role of cytokines in heart failure. Am Heart J 1998; 135: 181-86.
41. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
42. 2-dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482-88.
43. Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension 2005; 45: 126-32.
44. Brown, N.J.: US20056887679 (2005).
45. Daniel, J.E., Harris, M.R., Hokanson, G.C., Weiss, J.: US20067015232 ( 2006).
46. Eyjolesson, R.: US20067045511 (2006).
47. Montgomery, H.E., Martin, J.F., Erusalimsky, J.D.: US20067071183 ( 2006).
48. Heitsch, H.: US20066984660 (2006).
49. Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and onset of cardiovascular events. Results from the Health ABC Study. Circulation 2003; 108: 2317-22.
50. Yeh ETH, Anderson V, Pasceri V, et al. C-reactive protein. Linking inflammation to cardiovascular complications. Circulation 2001; 104: 974-975.
51. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 2054-59.
52. Garvey, D. S.: WO06127591A2 (2006).
53. Dzau VJ, Gnecchi M, Pachori AS. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 2005; 46: 7-18.
54. Dzau Q, Ishibashi M, Hiasa K-i, et al. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004; 44: 264-270.
55. Morishita R. Is vascular endothelial growth factor a missing link between hypertension and inflammation? Hypertension 2004; 44: 253-57.
56. Lim HS, Felmeden D, Lip GYH. Angiotensin II-mediated vascular inflammation: The balance between vascular endothelial growth factor and angiopoietins. Hypertension 2005; 45: e3.
57. Lerman A, Zeiher AM. Endothelial function. Cardiac events. Circulation 2005; 111: 363-68.
58. Levy BI. Beneficial effects of circulating progenitor endothelial cells activated by angiotensin receptor antagonists. Hypertension 2005; 45: 491-92.
59. Marin, P., Sorensen, S.: US20056881739 (2005),
60. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997; 79 (5A): 12-16.
61. Cody RJ. The integrated effects of angiotensin II. Am J Cardiol 1997; 79 (5A): 9-11.
62. 1 receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscl Thromb Vasc Biol 2000; 20: 2297-302.